BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tundo GR, Sbardella D, Santoro AM, Coletta A, Oddone F, Grasso G, Milardi D, Lacal PM, Marini S, Purrello R, Graziani G, Coletta M. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Pharmacol Ther 2020;213:107579. [PMID: 32442437 DOI: 10.1016/j.pharmthera.2020.107579] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Lottes EN, Cox DN. Homeostatic Roles of the Proteostasis Network in Dendrites. Front Cell Neurosci 2020;14:264. [PMID: 33013325 DOI: 10.3389/fncel.2020.00264] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Guo X. Localized Proteasomal Degradation: From the Nucleus to Cell Periphery. Biomolecules 2022;12:229. [DOI: 10.3390/biom12020229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang H, Chen J, Zhang M, Zhao M, Zhang L, Liu B, Wang S. Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma. Med Oncol 2022;39:55. [PMID: 35150316 DOI: 10.1007/s12032-021-01632-5] [Reference Citation Analysis]
4 Krishna-k K, Behnisch T, Sajikumar S. Modulation of the Ubiquitin-Proteasome System Restores Plasticity in Hippocampal Pyramidal Neurons of the APP/PS1 Alzheimer’s Disease-Like Mice. JAD 2022. [DOI: 10.3233/jad-215718] [Reference Citation Analysis]
5 Ware CA, Buhimschi CS, Zhao G, El Helou Y, Buhimschi IA. Amniotic Fluid Proteasome and Immunoproteasome in the Setting of Intra-Amniotic Infection, Inflammation, and Preterm Birth. Reprod Sci 2021;28:2562-73. [PMID: 33665784 DOI: 10.1007/s43032-021-00512-7] [Reference Citation Analysis]
6 Sbardella D, Tundo GR, Coletta M, Manni G, Oddone F. Dexamethasone Downregulates Autophagy through Accelerated Turn-Over of the Ulk-1 Complex in a Trabecular Meshwork Cells Strain: Insights on Steroid-Induced Glaucoma Pathogenesis. Int J Mol Sci 2021;22:5891. [PMID: 34072647 DOI: 10.3390/ijms22115891] [Reference Citation Analysis]
7 Wendt R, Lingitz MT, Laggner M, Mildner M, Traxler D, Graf A, Krotka P, Moser B, Hoetzenecker K, Kalbitz S, Lübbert C, Beige J, Ankersmit HJ. Clinical Relevance of Elevated Soluble ST2, HSP27 and 20S Proteasome at Hospital Admission in Patients with COVID-19. Biology (Basel) 2021;10:1186. [PMID: 34827178 DOI: 10.3390/biology10111186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Almendáriz-Palacios C, Gillespie ZE, Janzen M, Martinez V, Bridger JM, Harkness TAA, Mousseau DD, Eskiw CH. The Nuclear Lamina: Protein Accumulation and Disease. Biomedicines 2020;8:E188. [PMID: 32630170 DOI: 10.3390/biomedicines8070188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Guo H, Li Y, Liu Y, Chen L, Gao Z, Zhang L, Zhou N, Guo H, Shi B. Prognostic Role of the Ubiquitin Proteasome System in Clear Cell Renal Cell Carcinoma: A Bioinformatic Perspective. J Cancer 2021;12:4134-47. [PMID: 34093816 DOI: 10.7150/jca.53760] [Reference Citation Analysis]
10 Reboud-Ravaux M. [The proteasome - structural aspects and inhibitors: a second life for a validated drug target]. Biol Aujourdhui 2021;215:1-23. [PMID: 34397372 DOI: 10.1051/jbio/2021005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Fidor A, Cekała K, Wieczerzak E, Cegłowska M, Kasprzykowski F, Edwards C, Mazur-Marzec H. Nostocyclopeptides as New Inhibitors of 20S Proteasome. Biomolecules 2021;11:1483. [PMID: 34680116 DOI: 10.3390/biom11101483] [Reference Citation Analysis]
12 Song B, Shen S, Fu S, Fu J. HSPA6 and its role in cancers and other diseases. Mol Biol Rep 2022. [PMID: 35666422 DOI: 10.1007/s11033-022-07641-5] [Reference Citation Analysis]
13 Oddone F, Rossetti L, Parravano M, Sbardella D, Coletta M, Ziccardi L, Roberti G, Carnevale C, Romano D, Manni G, Parisi V. Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review. Pharmaceuticals (Basel) 2021;14:281. [PMID: 33804675 DOI: 10.3390/ph14030281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Qi S, Guan X, Zhang J, Yu D, Yu X, Li Q, Yin W, Cheng XD, Zhang W, Qin JJ. Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis. Mol Cancer 2022;21:70. [PMID: 35272681 DOI: 10.1186/s12943-022-01538-4] [Reference Citation Analysis]
15 de Felício R, Ballone P, Bazzano CF, Alves LFG, Sigrist R, Infante GP, Niero H, Rodrigues-Costa F, Fernandes AZN, Tonon LAC, Paradela LS, Costa RKE, Dias SMG, Dessen A, Telles GP, da Silva MAC, Lima AOS, Trivella DBB. Chemical Elicitors Induce Rare Bioactive Secondary Metabolites in Deep-Sea Bacteria under Laboratory Conditions. Metabolites 2021;11:107. [PMID: 33673148 DOI: 10.3390/metabo11020107] [Reference Citation Analysis]
16 Shi C, Cha J, Gong J, Wang S, Zeng P, Lian J, Zhang B, Hua Q, Lv J, Du C, Xie X, Zhang R. Amelioration of Experimental Autoimmune Encephalomyelitis in Alzheimer’s Disease Mouse Models: A Potential Role for Aβ. Cells 2022;11:1004. [DOI: 10.3390/cells11061004] [Reference Citation Analysis]
17 Jayaweera SPE, Wanigasinghe Kanakanamge SP, Rajalingam D, Silva GN. Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma. Front Oncol 2021;11:740796. [PMID: 34858819 DOI: 10.3389/fonc.2021.740796] [Reference Citation Analysis]
18 Zhu Y, Ju H, Lu H, Tang W, Lu J, Wang Q. The function role of ubiquitin proteasome pathway in the ER stress-induced AECII apoptosis during hyperoxia exposure. BMC Pulm Med 2021;21:379. [PMID: 34809635 DOI: 10.1186/s12890-021-01751-9] [Reference Citation Analysis]
19 Wang J, Fang Y, Fan RA, Kirk CJ. Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism. Int J Mol Sci 2021;22:11595. [PMID: 34769030 DOI: 10.3390/ijms222111595] [Reference Citation Analysis]
20 Lee TK, Kang IJ, Kim B, Sim HJ, Kim DW, Ahn JH, Lee JC, Ryoo S, Shin MC, Cho JH, Kim YM, Park JH, Choi SY, Won MH. Experimental Pretreatment with Chlorogenic Acid Prevents Transient Ischemia-Induced Cognitive Decline and Neuronal Damage in the Hippocampus through Anti-Oxidative and Anti-Inflammatory Effects. Molecules 2020;25:E3578. [PMID: 32781658 DOI: 10.3390/molecules25163578] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
21 Kwon S, Kim KB, Yeo Y, Lee W. Pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and efforts toward nanoparticulate delivery systems. J Pharm Investig 2021;51:483-502. [DOI: 10.1007/s40005-021-00532-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 García-Viñuales S, Sciacca MFM, Lanza V, Santoro AM, Grasso G, Tundo GR, Sbardella D, Coletta M, Grasso G, La Rosa C, Milardi D. The interplay between lipid and Aβ amyloid homeostasis in Alzheimer's Disease: risk factors and therapeutic opportunities. Chem Phys Lipids 2021;236:105072. [PMID: 33675779 DOI: 10.1016/j.chemphyslip.2021.105072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ghansah H, Debreceni IB, Fejes Z, Nagy B Jr, Kappelmayer J. The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets. Int J Mol Sci 2021;22:8955. [PMID: 34445660 DOI: 10.3390/ijms22168955] [Reference Citation Analysis]
24 Roeten MSF, van Meerloo J, Kwidama ZJ, Ter Huizen G, Segerink WH, Zweegman S, Kaspers GJL, Jansen G, Cloos J. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. Cells 2021;10:665. [PMID: 33802801 DOI: 10.3390/cells10030665] [Reference Citation Analysis]
25 Wang X, Peng H, Huang Y, Kong W, Cui Q, Du J, Jin H. Post-translational Modifications of IκBα: The State of the Art. Front Cell Dev Biol 2020;8:574706. [PMID: 33224945 DOI: 10.3389/fcell.2020.574706] [Reference Citation Analysis]
26 Li R, Okada H, Yamashita T, Nio K, Chen H, Li Y, Shimakami T, Takatori H, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S. FOXM1 Is a Novel Molecular Target of AFP-Positive Hepatocellular Carcinoma Abrogated by Proteasome Inhibition. IJMS 2022;23:8305. [DOI: 10.3390/ijms23158305] [Reference Citation Analysis]
27 Wu Y, Zhang C, Peng D, He S, Huang C, Qian J, Zhu W, Feng N, Gong Y, Li X, Zhou L. MiR-182-5p inhibits the tumorigenesis of clear cell renal cell carcinoma by repressing UBE2T. Hum Cell 2022. [PMID: 35129808 DOI: 10.1007/s13577-021-00661-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Persico M, Santoro AM, D’urso A, Milardi D, Purrello R, Cunsolo A, Gobbo M, Fattorusso R, Diana D, Stefanelli M, Tundo GR, Sbardella D, Coletta M, Fattorusso C. Modulation of the 20S Proteasome Activity by Porphyrin Derivatives Is Steered through Their Charge Distribution. Biomolecules 2022;12:741. [DOI: 10.3390/biom12060741] [Reference Citation Analysis]
29 Tundo GR, Sbardella D, Oddone F, Grasso G, Marini S, Atzori MG, Santoro AM, Milardi D, Bellia F, Macari G, Graziani G, Polticelli F, Cascio P, Parravano M, Coletta M. Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug. Biomolecules 2022;12:315. [DOI: 10.3390/biom12020315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Liang YH, Chen KH, Tsai JH, Cheng YM, Lee CC, Kao CH, Chan KY, Chen YT, Hsu WL, Yeh KH. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells. J Biomed Sci 2021;28:75. [PMID: 34758826 DOI: 10.1186/s12929-021-00769-9] [Reference Citation Analysis]
31 Benvenuto M, Ciuffa S, Focaccetti C, Sbardella D, Fazi S, Scimeca M, Tundo GR, Barillari G, Segni M, Bonanno E, Manzari V, Modesti A, Masuelli L, Coletta M, Bei R. Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells. Sci Rep 2021;11:19051. [PMID: 34561494 DOI: 10.1038/s41598-021-98450-6] [Reference Citation Analysis]
32 Tundo GR, Sbardella D, Oddone F, Kudriaeva AA, Lacal PM, Belogurov AA Jr, Graziani G, Marini S. At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention. Cancers (Basel) 2021;13:4852. [PMID: 34638337 DOI: 10.3390/cancers13194852] [Reference Citation Analysis]
33 Zagirova D, Autenried R, Nelson ME, Rezvani K. Proteasome Complexes and Their Heterogeneity in Colorectal, Breast and Pancreatic Cancers. J Cancer 2021;12:2472-87. [PMID: 33854609 DOI: 10.7150/jca.52414] [Reference Citation Analysis]
34 Gupta R, Sahu M, Srivastava D, Tiwari S, Ambasta RK, Kumar P. Post-translational modifications: Regulators of neurodegenerative proteinopathies. Ageing Res Rev 2021;68:101336. [PMID: 33775891 DOI: 10.1016/j.arr.2021.101336] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
35 Fogli S, Galimberti S, Gori V, Del Re M, Danesi R. Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice. Pharmacol Res 2021;167:105537. [PMID: 33684510 DOI: 10.1016/j.phrs.2021.105537] [Reference Citation Analysis]